CARA THERAPEUTICS, INC. CARA Cash Flow

Cara therapeutics, inc. (CARA)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13
Operating activities
Net loss
-113,335	-106,373	-98,414	-84,972	-79,206	-74,013	-67,538	-60,582	-52,688	-58,125	-65,920	-65,018	-68,792	-57,280	-44,838	-38,083	-30,693	-24,690	-19,332	-21,090	-19,051	-17,745	-15,666	-13,696	-4,714	-3,963	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
13,180	12,568	12,901	11,787	9,841	9,478	7,506	7,307	6,556	5,793	4,875	4,032	3,412	2,800	2,678	2,562	2,565	2,514	2,147	1,708	1,463	1,371	0	0	0	-	-	-	-
Depreciation and amortization
196	198	202	231	295	370	443	489	498	495	489	461	857	1,465	1,605	1,702	1,376	839	773	776	779	783	787	787	788	789	0	0	0
Amortization expense component of lease expense
616	601	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accretion of available-for-sale marketable securities, net
968	1,381	1,811	2,064	2,081	1,820	1,403	978	795	582	391	255	155	218	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Realized loss (gain) on sale of available-for-sale marketable securities
-	-	-	-	-	-5	-31	-13	-13	5	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of financing costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	117	0	0	0
Deferred rent costs
-	-	-	-	-	156	72	-132	-139	-148	-175	-274	83	114	233	542	301	289	285	277	271	265	257	251	244	238	0	0	0
Deferred revenue
-23,526	-19,747	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-1,452	-1,944	-2,980	-2,454	-2,023	0	0	0	-	-	-	-
Non-cash compensation expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Accrued interest and amortization of beneficial conversion feature on promissory notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,605	0	0	0
Changes in operating assets and liabilities:
Income tax receivable
189	152	494	511	-28	-67	-166	-87	219	-121	42	-48	29	468	213	358	314	184	361	193	169	139	31	-1	8	30	0	0	0
Other receivables
-172	45	591	489	935	803	96	-59	-899	36	-18	-76	855	7	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses
3,309	4,058	4,338	1,799	3,948	3,170	2,726	3,680	1,452	105	-3,328	-1,463	-594	-199	2,884	2,808	1,553	1,442	1,501	-646	-32	-388	1,368	2,275	2,047	1,736	0	0	0
Accounts payable and accrued expenses
4,061	6,043	6,577	213	6,435	5,116	6,731	5,363	-5,106	-3,027	448	-694	5,893	6,265	3,707	4,734	4,024	3,322	-488	1,123	-121	-12	1,099	452	1,335	722	0	0	0
Operating lease liability
-900	-879	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-120,002	-109,225	-102,420	-97,275	-31,359	-22,301	-9,353	1,288	-51,659	-54,827	-56,602	-59,652	-59,184	-47,381	-38,361	-33,275	-26,070	-21,478	-23,134	-19,807	-19,792	-17,642	-16,882	-15,835	1,557	2,829	0	0	0
Proceeds from maturities of available-for-sale marketable securities
229,764	253,584	285,639	241,481	227,945	175,300	102,250	102,950	92,650	82,156	86,136	73,886	70,486	80,380	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of available-for-sale marketable securities
-	-	-	-	-	79,808	31,275	14,475	14,575	8,755	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from the redemptions of available-for-sale marketable securities, at par
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of available-for-sale marketable securities
254,213	286,082	440,240	310,819	373,935	337,854	150,338	127,644	137,721	127,394	127,270	123,992	52,500	68,648	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Change in restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for construction in progress
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of property and equipment
-	18	42	70	82	73	49	49	52	58	127	589	717	717	655	166	22	20	0	0	0	-	-	-	-	-	-	-	-
Net cash provided by investing activities
-19,956	-30,516	-103,085	-750	-77,114	-82,819	-16,862	-10,240	-30,507	-36,500	-24,086	-21,380	57,105	45,018	-67,186	-81,969	-89,057	-91,677	0	0	0	-	-	-	-	-	-	-	-
Proceeds from initial public offering, net of issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	57,762	0	0	0	-	-	-	-
Proceeds from convertible promissory notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Financing costs on convertible promissory notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	70	0	0	0
Proceeds from the exercise of stock options
5,947	6,106	6,609	6,654	4,165	4,194	3,819	2,082	1,813	1,699	1,599	1,448	232	123	79	367	396	362	0	0	0	-	-	-	-	-	-	-	-
Net cash provided by financing activities
142,445	142,604	143,120	98,717	110,784	110,813	110,452	16,638	88,037	87,923	87,823	87,672	232	123	-143	75,598	75,627	75,593	75,885	234	224	57,990	57,570	57,480	64,796	8,416	0	0	0
Net decrease in cash, cash equivalents and restricted cash
2,487	2,863	-62,385	692	2,311	5,693	84,237	7,686	5,871	-3,404	7,135	6,640	-1,847	-2,240	-105,690	-39,646	-39,500	-37,562	52,723	-19,621	-19,616	40,306	40,660	41,634	66,348	11,240	0	0	0
Shares of common stock issued in exchange for consulting services
-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Conversion of convertible preferred stock to common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	65,586	0	0	0	-	-	-	-
Reclassification of prepaid IPO costs paid in 2013
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,465	0	0	0	-	-	-	-
Tenant improvements paid by landlord
-	-	-	-	-	-	-	-	-	-	-	-	-	1,094	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Subscriptions receivable
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unpaid IPO issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-